A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation

BACKGROUND: Presently, few options are available for refractory colorectal cancer (CRC). O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation is a frequent and early event in CRC tumourigenesis. This epigenetic silencing is a predictor of response to the alkylating drug temozolomide i...

Descripción completa

Detalles Bibliográficos
Autores principales: Calegari, M A, Inno, A, Monterisi, S, Orlandi, A, Santini, D, Basso, M, Cassano, A, Martini, M, Cenci, T, de Pascalis, I, Camarda, F, Barbaro, B, Larocca, L M, Gori, S, Tonini, G, Barone, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482728/
https://www.ncbi.nlm.nih.gov/pubmed/28427088
http://dx.doi.org/10.1038/bjc.2017.109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482728/
https://www.ncbi.nlm.nih.gov/pubmed/28427088
http://dx.doi.org/10.1038/bjc.2017.109

Ejemplares similares